Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 00509G209 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
| James B. Murray Jr. 13G | 5.0% |
4/7/2026
Event 4/4/2025
|
|
|
RA Capital Management, L.P.
13D/A
Amendment 4
|
29.5% |
3/17/2026
Event 3/13/2026
|
|
| RA Capital Management, L.P. | 29.5% | ||
| Peter Kolchinsky | 29.5% | ||
| Rajeev Shah | 29.5% | ||
| RA Capital Healthcare Fund, L.P. | 26.8% | ||
|
Franklin Resources, Inc.
13G/A
Amendment 1
|
3.8% |
11/4/2025
Event 9/30/2025
|
|
| Franklin Resources, Inc. | 3.8% | ||
| Charles B. Johnson | 0% | ||
| Rupert H. Johnson, Jr. | 0% | ||
|
Sands Capital Alternatives, LLC
13G/A
Amendment 2
|
5.6% |
8/13/2025
Event 6/30/2025
|
|
| Sands Capital Alternatives, LLC | 5.6% | ||
| Sands Capital Ventures Discovery Fund III, L.P. | 1.9% | ||
| Sands Capital Global Venture Fund II, L.P. | 1.9% | ||
| Sands Capital Life Sciences Pulse Fund, LLC | 1.9% | ||
| Sands Frank M. | 5.6% | ||
|
RA Capital Management, L.P.
13D/A
Amendment 3
|
24.8% |
3/31/2025
Event 3/27/2025
|
|
| RA Capital Management, L.P. | 24.8% | ||
| Peter Kolchinsky | 24.8% | ||
| Rajeev Shah | 24.8% | ||
| RA Capital Healthcare Fund, L.P. | 21.5% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 3 | 17.6 k | $39.1 k |
| 2026 Q2 | 97 | 47.9 M | $128 M |
| 2026 Q1 | 89 | 46.0 M | $109 M |
| 2025 Q4 | 72 | 35.7 M | $75.2 M |
| 2025 Q3 | 72 | 35.7 M | $61.1 M |
| 2025 Q2 | 75 | 37.6 M | $43.6 M |
| 2025 Q1 | 85 | 40.3 M | $44.8 M |
| 2024 Q4 | 84 | 42.5 M | $73.2 M |
| 2024 Q3 | 80 | 43.7 M | $108 M |
| 2024 Q2 | 89 | 43.7 M | $106 M |
| 2024 Q1 | 89 | 43.5 M | $176 M |
| 2023 Q4 | 77 | 38.6 M | $148 M |
| 2023 Q3 | 77 | 43.7 M | $181 M |
| 2023 Q2 | 61 | 26.3 M | $127 M |
| 2023 Q1 | 67 | 28.1 M | $114 M |
| 2022 Q4 | 69 | 29.3 M | $158 M |
| 2022 Q3 | 58 | 27.8 M | $278 M |
| 2022 Q2 | 49 | 25.6 M | $120 M |
| 2022 Q1 | 60 | 27.1 M | $106 M |
| 2021 Q4 | 53 | 25.6 M | $173 M |
| 2021 Q3 | 42 | 24.1 M | $357 M |